Together with Sapphiros, The US Biomedical Advanced Research and Development Authority (BARDA) is developing an over the counter (OTC), single-use, low-cost antigen test that can detect and differentiate between respiratory viruses. The NowFuture Digital Flu/COVID Test incorporates a clear digital readout and built-in connectivity to a smartphone app for results access and sharing.
If U.S. Food and Drug Administration (FDA)-cleared, it would be the first OTC digital-read test for respiratory infectious diseases.
Diagnostics that can be performed at home can empower individuals with actionable information about their infection status so that they can take steps to prevent the spread of the disease and seek medical care and treatment early in the course of any infection.
See more in BARDA’s Detection, Diagnostics, and Devices Infrastructure (DDDI) portfolio: https://www.medicalcountermeasures.gov/barda/dddi
-ends-
